Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing
- PMID: 12847523
- DOI: 10.1038/nm900
Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing
Abstract
Conventional gene therapy of hemophilia A relies on the transfer of factor VIII (FVIII; encoded by the F8 gene) cDNA. We carried out spliceosome-mediated RNA trans-splicing (SMaRT) to repair mutant FVIII mRNA. A pre-trans-splicing molecule (PTM) corrected endogenous FVIII mRNA in F8 knockout mice with the hemophilia A phenotype, producing sufficient functional FVIII to correct the hemophilia A phenotype. This is the first description of phenotypic correction of a genetic defect by RNA repair in a knockout animal model. Our results indicate the feasibility of using SMaRT to repair RNA for the treatment of genetic diseases.
Comment in
-
Express delivery.Nat Med. 2003 Aug;9(8):977. doi: 10.1038/nm0803-977. Nat Med. 2003. PMID: 12894139 No abstract available.
-
Coaxing coagulation with RNA and cell fragments.Nat Med. 2003 Aug;9(8):991-2. doi: 10.1038/nm0803-991. Nat Med. 2003. PMID: 12894156 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
